The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
Open accessAbstract
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder cancer, as substantial revisions were made in the 2017 updates, such as new recommendations for nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab. The complete version of the NCCN Guidelines for Bladder Cancer addresses additional aspects of the management of bladder cancer, including non-muscle-invasive urothelial bladder cancer and nonurothelial histologies, as well as staging, evaluation, and follow-up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395
Comprehensive molecular characterization of urothelial bladder carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/za09-dk57 · Cited by 2,990
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Grossman, H. B., Natale, R. B., Tangen, C. M., Speights, V. O., Vogelzang, N. J., Trump, D. L., White, R. W. D., Sarosdy, M. F., Wood, D. P., Raghavan, D., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022148 · Cited by 2,668
von der Maase, H., Hansen, S. W., Roberts, J. T., Dogliotti, L., Oliver, T., Moore, M. J., Bodrogi, I., Albers, P., Knuth, A., Lippert, C. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3068 · Cited by 2,279
Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199
Humphrey, P. A., Moch, H., Cubilla, A. L., Ulbright, T. M., & Reuter, V. E. (2016) · European Urology · doi:10.1016/j.eururo.2016.02.028 · Cited by 1,916
von der Maase, H., Sengelov, L., Roberts, J. T., Ricci, S., Dogliotti, L., Oliver, T., Moore, M. J., Zimmermann, A., & Arning, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.757 · Cited by 1,850
Sharma, P., Retz, M., Siefker-Radtke, A., Baron, A., Necchi, A., Bedke, J., Plimack, E. R., Vaena, D., Grimm, M.-O., Bracarda, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30065-7 · Cited by 1,736
Self-citationRadiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer
James, N. D., Hussain, S. A., Hall, E., Jenkins, P., Tremlett, J., Rawlings, C., Crundwell, M., Sizer, B., Sreenivasan, T., Hendron, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106106 · Cited by 962
International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), T. E. O. F. R. A. T. O. C. G.-U. T. C. G. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.3139 · Cited by 949
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
Chang, S. S., Bochner, B. H., Chou, R., Dreicer, R., Kamat, A. M., Lerner, S. P., Lotan, Y., Meeks, J. J., Michalski, J. M., Morgan, T. M., et al. (2017) · Journal of Urology · doi:10.1016/j.juro.2017.04.086 · Cited by 938
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1509660 · Cited by 872
Massard, C., Gordon, M. S., Sharma, S., Rafii, S., Wainberg, Z. A., Luke, J., Curiel, T. J., Colon-Otero, G., Hamid, O., Sanborn, R. E., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.9761 · Cited by 840
De Santis, M., Bellmunt, J., Mead, G., Kerst, J. M., Leahy, M., Maroto, P., Gil, T., Marreaud, S., Daugaard, G., Skoneczna, I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.3571 · Cited by 778
Bellmunt, J., Théodore, C., Demkov, T., Komyakov, B., Sengelov, L., Daugaard, G., Caty, A., Carles, J., Jagiello-Gruszfeld, A., Karyakin, O., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5534 · Cited by 766
Sternberg, C. N., de Mulder, P. H. M., Schornagel, J. H., Théodore, C., Fossa, S. D., van Oosterom, A. T., Witjes, F., Spina, M., van Groeningen, C. J., de Balincourt, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2638 · Cited by 628
Apolo, A. B., Infante, J. R., Balmanoukian, A., Patel, M. R., Wang, D., Kelly, K., Mega, A. E., Britten, C. D., Ravaud, A., Mita, A. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6795 · Cited by 585
PD-1 blockade in tumors with mismatch repair deficiency.
Le, D. T., Uram, J. N., Wang, H., Bartlett, B., Kemberling, H., Eyring, A., Skora, A., Azad, N. S., Laheru, D. A., Donehower, R. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.lba100 · Cited by 565
Sternberg, C. N., de Mulder, P., Schornagel, J. H., Theodore, C., Fossa, S. D., van Oosterom, A. T., Witjes, J. A., Spina, M., van Groeningen, C. J., Duclos, B., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.032 · Cited by 542
Bellmunt, J., von der Maase, H., Mead, G. M., Skoneczna, I., De Santis, M., Daugaard, G., Boehle, A., Chevreau, C., Paz-Ares, L., Laufman, L. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.6979 · Cited by 526
Skinner, D. G., Daniels, J. R., Russell, C. A., Lieskovsky, G., Boyd, S. D., Nichols, P., Kern, W., Sakamoto, J., Krailo, M., & Groshen, S. (1991) · Journal of Urology · doi:10.1016/s0022-5347(17)38368-4 · Cited by 524
Shipley, W. U., Winter, K., Kaufman, D. S., Lee, W. R., Heney, N. M., Tester, W., Donnelly, B. J., Venner, P. M., Perez, C. A., Murray, K. J., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3576 · Cited by 496
Coppin, C., Gospodarowicz, M. K., James, K. W., Tannock, I. F., Zee, B. C.-Y., Carson, J., Pater, J. L., & Sullivan, L. D. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.11.2901 · Cited by 472
Mak, R. H., Hunt, D., Shipley, W. U., Efstathiou, J. A., Tester, W. J., Hagan, M. P., Kaufman, D. S., Heney, N. M., & Zietman, A. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.5548 · Cited by 465
Self-citationLeissner, J., Hohenfellner, R., Thüroff, J. W., & Wolf, H. K. (2000) · BJU International · doi:10.1046/j.1464-410x.2000.00614.x · Cited by 444
Efstathiou, J. A., Spiegel, D. Y., Shipley, W. U., Heney, N. M., Kaufman, D. S., Niemierko, A., Coen, J. J., Skowronski, R. Y., Paly, J. J., McGovern, F. J., et al. (2012) · European Urology · doi:10.1016/j.eururo.2011.11.010 · Cited by 435
Self-citationGakis, G., Efstathiou, J., Lerner, S. P., Cookson, M. S., Keegan, K. A., Guru, K. A., Shipley, W. U., Heidenreich, A., Schoenberg, M. P., Sagaloswky, A. I., et al. (2013) · European Urology · doi:10.1016/j.eururo.2012.08.009 · Cited by 422
Self-citationLeow, J. J., Martin-Doyle, W., Rajagopal, P. S., Patel, C. G., Anderson, E. M., Rothman, A. T., Cote, R. J., Urun, Y., Chang, S. L., Choueiri, T. K., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.08.033 · Cited by 411
Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.
McCaffrey, J. A., Hilton, S., Mazumdar, M., Sadan, S., Kelly, W. K., Scher, H. I., & Bajorin, D. F. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.1853 · Cited by 371
WINQUIST, E., KIRCHNER, T. S., SEGAL, R., CHIN, J., LUKKA, H., & on behalf of the GENITOURINARY CANCER DISEASE SITE GROUP OF CANCER CARE ONTARIO PROGRAM IN EVIDENCE-BASED CARE PRACTICE GUIDELINES INITIATIVE (2004) · Journal of Urology · doi:10.1097/01.ju.0000090967.08622.33 · Cited by 358
Ploussard, G., Daneshmand, S., Efstathiou, J. A., Herr, H. W., James, N. D., Rödel, C. M., Shariat, S. F., Shipley, W. U., Sternberg, C. N., Thalmann, G. N., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.02.038 · Cited by 355
Self-citationPlimack, E. R., Bellmunt, J., Gupta, S., Berger, R., Chow, L. Q. M., Juco, J., Lunceford, J., Saraf, S., Perini, R. F., & O'Donnell, P. H. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30007-4 · Cited by 335
Self-citationPlimack, E. R., Hoffman-Censits, J. H., Viterbo, R., Trabulsi, E. J., Ross, E. A., Greenberg, R. E., Chen, D. Y. T., Lallas, C. D., Wong, Y.-N., Lin, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.2465 · Cited by 287
Self-citationLorusso, V, Pollera, C. F., Antimi, M., Luporini, G., Gridelli, C., Frassineti, G. L., Oliva, C., Pacini, M., & De Lena, M. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00030-6 · Cited by 286
Pembrolizumab for the treatment of non-small cell lung cancer
Lim, S. H., Sun, J.-M., Lee, S.-H., Ahn, J. S., Park, K., & Ahn, M.-J. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1145652 · Cited by 282
McConkey, D. J., Choi, W., Shen, Y., Lee, I.-L., Porten, S., Matin, S. F., Kamat, A. M., Corn, P., Millikan, R. E., Dinney, C., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.08.034 · Cited by 277
Self-citationMillikan, R., Dinney, C., Swanson, D., Sweeney, P., Ro, J. Y., Smith, T. L., Williams, D., & Logothetis, C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.20.4005 · Cited by 271
Phase II Trial of Weekly Paclitaxel in Patients With Previously Treated Advanced Urothelial Cancer
Vaughn, D. J., Broome, C. M., Hussain, M., Gutheil, J. C., & Markowitz, A. B. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.4.937 · Cited by 269
Phase II Trial of Gemcitabine Plus Cisplatin in Patients With Metastatic Urothelial Cancer
Kaufman, D., Raghavan, D., Carducci, M., Levine, E. G., Murphy, B., Aisner, J., Kuzel, T., Nicol, S., Oh, W., & Stadler, W. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.9.1921 · Cited by 257
Gray, P. J., Fedewa, S. A., Shipley, W. U., Efstathiou, J. A., Lin, C. C., Zietman, A. L., & Virgo, K. S. (2013) · European Urology · doi:10.1016/j.eururo.2012.11.015 · Cited by 243
Self-citationEfstathiou, J. A., Bae, K., Shipley, W. U., Kaufman, D. S., Hagan, M. P., Heney, N. M., & Sandler, H. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.5776 · Cited by 222
Self-citationNeoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome.
Herr, H. W., Bajorin, D. F., & Scher, H. I. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1298 · Cited by 203
Self-citationEffectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer
Galsky, M. D., Stensland, K. D., Moshier, E., Sfakianos, J. P., McBride, R. B., Tsao, C.-K., Casey, M., Boffetta, P., Oh, W. K., Mazumdar, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.1076 · Cited by 192
Fedeli, U., Fedewa, S. A., & Ward, E. M. (2011) · Journal of Urology · doi:10.1016/j.juro.2010.09.015 · Cited by 187
Picozzi, S., Ricci, C., Gaeta, M., Ratti, D., Macchi, A., Casellato, S., Bozzini, G., & Carmignani, L. (2012) · Journal of Urology · doi:10.1016/j.juro.2012.08.017 · Cited by 180
Urinary Bladder Cancer: Role of MR Imaging
Verma, S., Rajesh, A., Prasad, S. R., Gaitonde, K., Lall, C. G., Mouraviev, V., Aeron, G., Bracken, R. B., & Sandrasegaran, K. (2012) · RadioGraphics · doi:10.1148/rg.322115125 · Cited by 178
von der Maase, H., Sengelov, L., Roberts, J. T., Ricci, S., Dogliotti, L., Oliver, T., Moore, M. J., Zimmermann, A., & Arning, M. (2006) · Journal of Urology · doi:10.1016/s0022-5347(05)00370-8 · Cited by 169
De Santis, M., Bellmunt, J., Mead, G., Kerst, J. M., Leahy, M., Maroto, P., Skoneczna, I., Marreaud, S., de Wit, R., & Sylvester, R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4924 · Cited by 169
Mitin, T., Hunt, D., Shipley, W. U., Kaufman, D. S., Uzzo, R., Wu, C.-L., Buyyounouski, M. K., Sandler, H., & Zietman, A. L. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70255-9 · Cited by 163
Self-citationPapamichael, D., Gallagher, C., Oliver, R. T. D., Johnson, P., & Waxman, J. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.106 · Cited by 118
Baumann, B. C., Bosch, W. R., Bahl, A. K., Birtle, A. J., Breau, R. H., Challapalli, A., Chang, A. J., Choudhury, A., Daneshmand, S., El-Gayed, A. A. H., et al. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.04.032 · Cited by 57
Self-citationAthanazio, D. A., & Trpkov, K. (2016) · Applied cancer research/Applied Cancer Research · doi:10.1186/s41241-016-0003-7 · Cited by 11
Cited by
Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer
Tutt, A. N. J., Garber, J. E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., Gelber, R. D., de Azambuja, E., Fielding, A., Balmaña, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105215 · Cited by 1,729
Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA
Dudley, J. C., Schroers-Martin, J., Lazzareschi, D. V., Shi, W. Y., Chen, S. B., Esfahani, M. S., Trivedi, D., Chabon, J. J., Chaudhuri, A. A., Stehr, H., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0825 · Cited by 253
Product review: Avelumab, an anti-PD-L1 antibody
Collins, J. M., & Gulley, J. L. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1551671 · Cited by 91
Clinical therapies and nano drug delivery systems for urinary bladder cancer
Jain, P., Kathuria, H., & Momin, M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107871 · Cited by 89
Metadata
- Authors
- Spiess, P. E., Agarwal, N., Bangs, R., Boorjian, S. A., Buyyounouski, M. K., Clark, P. E., Downs, T. M., Efstathiou, J. A., Flaig, T. W., Friedlander, T., Greenberg, R. E., Guru, K. A., Hahn, N., Herr, H. W., Hoimes, C., Inman, B. A., Jimbo, M., Kader, A. K., Lele, S. M., Meeks, J. J., Michalski, J., Montgomery, J. S., Pagliaro, L. C., Pal, S. K., Patterson, A., Plimack, E. R., Pohar, K. S., Porter, M. P., Preston, M. A., Sexton, W. J., Siefker-Radtke, A. O., Sonpavde, G., Tward, J., Wile, G., Dwyer, M. A., & Gurski, L. A.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2017-10
- Volume
- 15
- Issue
- 10
- Pages
- 1240-1267
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W2738200477
- Cited by
- 268
- References
- 59
- FWCI
- 41.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.